X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs AJANTA PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA AJANTA PHARMA ASTRAZENECA PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 90.3 20.1 449.8% View Chart
P/BV x 12.9 8.7 148.1% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
AJANTA PHARMA
Mar-16
ASTRAZENECA PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2851,720 74.7%   
Low Rs6341,103 57.5%   
Sales per share (Unadj.) Rs189.6194.6 97.4%  
Earnings per share (Unadj.) Rs-0.245.2 -0.5%  
Cash flow per share (Unadj.) Rs3.850.3 7.6%  
Dividends per share (Unadj.) Rs08.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs68.6132.0 52.0%  
Shares outstanding (eoy) m25.0088.77 28.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.17.3 69.8%   
Avg P/E ratio x-4,712.731.2 -15,097.6%  
P/CF ratio (eoy) x249.628.1 889.3%  
Price / Book Value ratio x14.010.7 130.8%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m23,988125,299 19.1%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,6052,570 62.4%   
Avg. sales/employee Rs Th3,040.2NM-  
Avg. wages/employee Rs Th1,029.2NM-  
Avg. net profit/employee Rs Th-3.3NM-  
INCOME DATA
Net Sales Rs m4,74017,275 27.4%  
Other income Rs m92166 55.4%   
Total revenues Rs m4,83217,442 27.7%   
Gross profit Rs m-1305,807 -2.2%  
Depreciation Rs m101451 22.5%   
Interest Rs m049 0.0%   
Profit before tax Rs m-1395,474 -2.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,460 0.3%   
Profit after tax Rs m-54,014 -0.1%  
Gross profit margin %-2.733.6 -8.1%  
Effective tax rate %-3.726.7 -13.7%   
Net profit margin %-0.123.2 -0.5%  
BALANCE SHEET DATA
Current assets Rs m2,7267,639 35.7%   
Current liabilities Rs m2,4352,715 89.7%   
Net working cap to sales %6.128.5 21.6%  
Current ratio x1.12.8 39.8%  
Inventory Days Days7443 170.6%  
Debtors Days Days4179 51.8%  
Net fixed assets Rs m1,0356,914 15.0%   
Share capital Rs m50177 28.3%   
"Free" reserves Rs m94211,442 8.2%   
Net worth Rs m1,71611,721 14.6%   
Long term debt Rs m0149 0.0%   
Total assets Rs m4,15614,814 28.1%  
Interest coverage xNM112.9-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.11.2 97.8%   
Return on assets %-0.127.4 -0.4%  
Return on equity %-0.334.2 -0.9%  
Return on capital %046.5 0.0%  
Exports to sales %5.755.1 10.3%   
Imports to sales %6.56.0 107.6%   
Exports (fob) Rs m2709,527 2.8%   
Imports (cif) Rs m3061,038 29.5%   
Fx inflow Rs m37510,422 3.6%   
Fx outflow Rs m4701,678 28.0%   
Net fx Rs m-968,744 -1.1%   
CASH FLOW
From Operations Rs m-83,264 -0.2%  
From Investments Rs m-146-2,093 7.0%  
From Financial Activity Rs m862-1,186 -72.7%  
Net Cashflow Rs m709-15 -4,787.2%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 1.6 19.4%  
FIIs % 15.7 7.6 206.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.0 53.5%  
Shareholders   12,856 20,968 61.3%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  NOVARTIS  PANACEA BIOTECH  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Pharma Stocks Among Top Gainers(01:30 pm)

After opening the day in green, share markets in India witnessed choppy trades and are presently trading marginally above the dotted line.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 22, 2017 03:23 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - DR. REDDYS LAB COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS